orca-bio
(2)
Ivan Dimov and the 48-Hour Problem
He began by building hammers and hunting for nails. At Stanford, Ivan Dimov reversed the method - then spent nearly a decade turning a delicate cell-sorting idea into an industrial system.
Nathaniel Fernhoff
Nathaniel Fernhoff is the CEO and Co-founder of Orca Bio, a late-stage biotechnology company headquartered in Menlo Park, California, developing high-precision allogeneic T-cell immunotherapies to treat blood cancers and autoimmune diseases. Holding a Ph.D. in Molecular and Cell Biology from UC Berkeley and dual Bachelor's degrees in Biological Sciences and Mathematics from Stanford, Fernhoff co-founded Orca Bio in 2016 based on decades-old Stanford research. He rose from Chief Scientific Officer to CEO in May 2025, leading the company through a landmark Phase 3 clinical trial for Orca-T - showing 78% survival free from chronic graft-versus-host disease versus 38% for standard-of-care - a BLA submission under FDA Priority Review, and a $250M Series F round bringing total funding to over $625M. With a 100,000-square-foot manufacturing facility in Sacramento capable of producing ~3,000 cell therapy products per year, Fernhoff is steering Orca Bio toward potential commercialization and a cure for blood diseases without compromise.